Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.
03 February 2016 | EATG
Non-specific or antiretroviral-based vaginal gels failed to work but new formulations offer hope.
11 January 2016 | IAVI Report
Will Nutland proposes that instead of the Hollywood style ‘end of AIDS moment’ fantasy, the end of AIDS will be a process with a number of emerging endpoints. In this eye-opening talk, Will introduces PrEP and rectal microbicides and discusses their efficacy and levels of acceptability. He surmises that the end might happen without us even noticing.
10 November 2015 | TEDx Talks / You Tube
How do things stand with the development of topical agents for HIV prevention? In the age of oral pre-exposure prophylaxis (PrEP) and treatment as prevention, does it matter anymore? And if lessons learned by researchers in the VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial -- discussed most often in terms of its failure -- help make future HIV clinical trials more effective, can we really call it a failure?
02 November 2015 | The Body Pro
The benevolent powers of the vaginal microbiome are even greater than we thought. In addition to aiding fertilization and protecting fetuses during pregnancy, healthy vaginal mucus that’s full of good bacteria can trap and immobilize HIV particles. The study examined the cervicovaginal mucus, or CVM, of 31 women and tested its ability to immobilize HIV particles. CVM samples that contained higher concentrations of D-lactic acid, which only bacteria can produce, did far better than others. The D-lactic acid wasn’t itself a barrier to HIV, but an indicator of something else going on that made certain types of CVM better at trapping the virus than others.
That something was Lactobacillus crispatus, a species of bacteria that could change the way we think about HIV prevention.
08 October 2015 | Slate
An experimental silicone vaginal ring with separate compartments may be able to deliver both tenofovir for prevention of HIV infection and acyclovir for prevention of genital herpes and potentially other sexually transmitted infections (STIs), according to a report at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last weekin San Diego.
28 September 2015 | HIVandHepatitis.com
A microbicide gel initially intended to offer protection against HIV has been found to be effective against herpes. Herpes is one of the most common sexually transmitted diseases in South Africa. In the latest study, published in the New England Journal of Medicine, researchers from the Centre for the Aids Programme of Research in South Africa (Caprisa) showed that Tenofovir gel halved the risk of developing herpes simplex virus type 2 – a virus that is a leading cause of genital ulcers.
13 August 2015 | Independent Online (South Africa)
HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.
19 July 2015 | AVAC
In a first for HIV prevention, researchers have completed follow-up of participants in a pivotal Phase III trial that tested a vaginal ring for preventing HIV in women. The ring, which contains the ARV dapivirine, is meant to be worn for a month at a time. More than 2,600 African women took part in ASPIRE, one of two Phase III trials designed to support potential licensure of the ring. Results are expected early 2016.
29 June 2015 | Eurekalert Medicine & Health
Scientists at the University of York, in conjunction with the York Clinical Research Facility, will start the first phase of trials looking into a new way to prevent HIV transmission.
18 February 2015 | HIV / AIDS News From Medical News Today